Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

49 results about "Icodextrin" patented technology

Icodextrin (INN, USAN) is a colloid osmotic agent, derived from maltodextrin, used in form of an aqueous solution for peritoneal dialysis under the trade name Extraneal, and after gynecological laparoscopic surgery for the reduction of post-surgical adhesions (fibrous bands that form between tissues and organs) under the trade name Adept.

Preparation method of icodextrin for starch-based peritoneal dialysis solution

The present invention discloses a preparation method of icodextrin for a starch-based peritoneal dialysis solution. According to the technical scheme of the invention, native starch is adopted as a raw material, and then a starch solution with the concentration thereof to be 5% to 15% is prepared by using a phosphate buffered solution. At a certain temperature and a certain pH value, the starch solution is firstly subjected to enzymolysis by using alpha-amylase, and then the gelatinized starch is subjected to debranching by using a debranching enzyme. The enzymatic hydrolysate is subjected to alcohol precipitation, ultrafiltration, gel chromatographic column separation and purification, and then the weight-average and number-average molecular weights thereof and the alpha-1, 6 glycosidic bond thereof meet the requirements at the same time. The content of alpha-1, 6 glycosidic bond in icodextrin is smaller than 10%, and the weight-average molecular weight thereof is 13000 to 19000 Da. The number-average molecular weight thereof is 5000 to 6500 Da. The preparation method of icodextrin for the starch-based peritoneal dialysis solution is high in yield, good in quality and relatively low in cost. Meanwhile, the defects of the conventional icodextrin preparation process in the prior art are overcome.
Owner:SOUTH CHINA UNIV OF TECH

Use of a mixture of modified glucose polymers for reducing tumor metastasis

The present invention relates to a solution, in particular a pharmaceutically acceptable solution, comprising icodextrin and hydroxyalkyl starch (HAS), wherein the icodextrin is present at a concentration of from 1 to 7.5 % (w / v) and wherein said HAS is present at a concentration of from 1 to 15 % (w / v). The present invention further relates to the aforesaid pharmaceutically acceptable solution for use as a medicament and for use in (e.g., in methods of) preventing metastasis formation and / or relapse by administration to a body cavity of a subject afflicted with cancer. The present invention further relates to a kit comprising icodextrin and HAS in pre- weighed amounts and a pharmaceutically acceptable means of dissolving the same, to a device comprising a pharmaceutically acceptable solution of the present invention and means for administering the same, as well as to a pharmaceutically acceptable solution comprising icodextrin and hydroxyalkyl starch at a total concentration in the range of from 1 to 20 % (w / v), wherein the weight ratio of the icodextrin relative to the hydroxyalkyl starch is in the range of from 0.05:1 to 5:1, for use in preventing metastasis formation and / or relapse by administration to a body cavity of a subject afflicted with cancer.
Owner:FRESENIUS KABI DEUT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products